Investigating Visual Verticality Disorder and Lateropulsion in a Neurosurgical Cohort of Patients With Brain Tumours

NCT06951659 | Recruiting DMC

• 1 other identifier: RGS5125
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The overall objective of this research is to investigate the clinical characteristics pre- and post-brain tumour resection with a focus on visual verticality disorder, and lateropulsion, including neuroimaging analysis, of a neurosurgical cohort of patients with brain tumours. This prospective observational cohort study will investigate clinical and neuroimaging characteristics and the relationship between lateropulsion and visual verticality disorder in patients pre- and post-brain tumour resection. Patients (aged 18-80 years, with a confirmed diagnosis of brain tumour and a neurosurgical pathway) will be enrolled from the state-wide Neurosurgery Service of Western Australia at Sir Charles Gairdner Hospital.

Conditions

Brain Tumours

Keywords

Brain tumour; lateropulsion; visual verticality perception; graviceptive neglect; neurosurgery; neuroimaging; structural connectivity; acute care; rehabilitation; neuro-oncology

Outcome Measures

Primary Outcomes (5)

• Visual Verticality Perception (VV, visual graviceptive neglect)

  Change in VV: assessment using the bucket test method.

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• Subjective Haptic Vertical (SHV) test

  The SHV test, the participant is blindfolded and asked to align a movable rod or bar to what they perceive as vertical using only their sense of touch (haptic input). This is to isolate somatosensory and vestibular input from visual cues. This will be performed in an upright sitting position to explore graviceptive function and verticality perception.

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• The Four Point Pusher's Score (4PPS)

  The 4PPS is a four-item scale that measures lateropulsion or pusher syndrome. The score for each component is rated on a scale from 0 to 3 (0 to 4 for standing) and the score is based on the severity of resistance or the tilt angle when the patient begins to resist the passive movement. The score for diagnosis of Pusher behaviour is \>2 points.

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• Scale for Contraversive Pushing

  A 3-item scale that measures lateropulsion or pusher syndrome, by rating the action / reaction of patients required to keep or change position. Scores: 0= no contraversive pushing 1. minimum score for each item 2. maximum score Score on each component \>1 indicative of lateropulsion.

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• Resource Utilisation Group Activities of Daily Living (RUG ADL)

  The RUG-ADL score is a 4-item scale measuring motor function with activities of bed mobility, toileting, transfer and eating. The score measures the degree of assistance a patient requires for these activities. The total RUG-ADL score is calculated by summing the scores for the four ADL variables. The total RUG-ADL score ranges from a minimum score of 4 to a maximum score of 18. The higher the score the more assistance the patient requires to complete the four ADL variables.

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

Other Outcomes (16)

• Retropulsion

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• MD Anderson Symptom Inventory - Brain Tumour (MDASI-BT)

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

• Rehabilitation Complexity Scale - extended version (RCS-E v13)

  Pre-brain tumour resection, acute post-brain tumour resection (day 1-5), and day 30 post-brain tumour resection (day 30)

Study Arms (1)

Patients with a brain tumour.

This study will investigate a neurosurgical cohort of patients pre and post-brain tumour resection.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients admitted to the State-Wide Neurosurgical Service of Western Australia (WA) at Sir Charles Gairdner Hospital.

You may qualify if:

• Patients of age 18 to 80 admitted to SCGH under the neurosurgery team with a confirmed diagnosis of a brain tumour.
• Only patients who undergo partial or full brain tumour resection and are medically stable.
• Able to provide written informed consent or consent provided by a Research Decision-Maker with the approval of an Independent Medical Practitioner (IMP) as per the Guardianship and Administration Act 1990 (GAA).
• Patients with a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required.

You may not qualify if:

• Patients who undergo only biopsy will not be included.
• Unable to follow any instructions and complete assessments due to significant medical deterioration.
• Patients who are pregnant.
• Current diagnosis of COVID-19 or respiratory syncytial virus (RSV), or any type of influenza.
• Patients without a support network that enables them to accommodate to travel commitments for assessments if travel to the hospital is required.
• An Advanced Care Health Directive prohibiting decision making by Research Decision-Maker.

Sponsors & Collaborators

• The University of Western Australia: lead
• Sir Charles Gairdner Hospital: collaborator
• University of Sao Paulo: collaborator

Study Sites (1)

Sir Charles Gairdner Osborne Park Health Care Group

Perth, Western Australia, 6009, Australia

RECRUITING

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Taiza GS Edwards, PhD

  The University of Western Australia

  PRINCIPAL INVESTIGATOR

• Anne-Marie Hill, PhD

  The University of Western Australia

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jimena Garcia-Vega, MSc

CONTACT

+61 434864334; jimena.garcia-vega@research.uwa.edu.au

Anne-Marie Hill, PhD

CONTACT

+61 400737570; anne-marie.hill@uwa.edu.au

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PhD Candidate

Study Record Dates

• First Submitted: April 13, 2025
• First Posted: April 30, 2025
• Study Start: June 12, 2025
• Primary Completion: December 12, 2025
• Study Completion: December 30, 2025
• Last Updated: June 19, 2025

Record last verified: 2025-04

Locations

AU (1)